Beckman Coulter Diagnostics, a Danaher company, announced that its new DxC 500i Clinical Analyzer has received 510(k) clearance from the U.S. Food and Drug Administration. This integrated system combines clinical chemistry and immunoassay capabilities.
The DxC 500i offers high throughput, capable of performing up to 800 clinical chemistry tests per hour and 100 immunoassay tests per hour. This efficiency is critical for modern healthcare laboratories, especially those within Integrated Delivery Networks (IDNs).
Featuring FlexMode operations and dynamic sample handling, the analyzer is designed to optimize rapid throughput in a compact footprint. The DxC 500i has been available in countries accepting CE mark since July 2024, and its FDA clearance now opens the U.S. market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.